




## Business Divisions Pharmaceuticals


Roche Pharmaceuticals focuses on delivering differentiated medicines that make a difference to patients' lives. In 2008 the division recorded CHF 35.6 billion in sales and invested over CHF 8 billion in research and development. The result of our consistent investment is a product pipeline that is recognised for both its breadth and quality.

Sales by region 2008

Sales by therapeutic area 2008



- North America 41% (+70%)
- Western Europe 29% (+8%)
- Japan 9% (+4%)
- CEMAI 9% (+12%)
- Asia Pacific 5% (+9%)
- Latin America 6% (+16%)
- Other 1%



- Oncology 55% (+15.5%)
- Inflammation/Transplantation 9% (+19%)
- Virology 10% (+15.5%)
- Metabolism/Bone 8% (-27.1%)
- Anaemia 4% (-11.1%)
- Other 19%


Growth rates in local currencies & excl. Tamiflu pandemic sales

## Diagnostics


Roche Diagnostics is the world's largest in-vitro diagnostics company, with a portfolio covering early detection and diagnosis of disease to selecting and monitoring treatment. In 2008 the division reached CHF 9.7 billion in sales and invested nearly CHF 1 billion in research and development. Our programmes for discovering and developing new disease markers combined with cutting-edge instrumentation and data management systems, provide us with a unique advantage in the development of personalised healthcare.

Sales by region 2008

Sales by business area 2008



- Europe/Middle East/Africa 54% (+7%)
- North America 26% (+14%)
- Asia-Pacific 9% (+18%)
- Latin America 6% (+18%)
- Japan 5% (+7%)
- Other 1%



- Professional Diagnostics 46% (+9%)
- Diabetes Care 31% (-7%)
- Molecular Diagnostics 11% (+5%)
- Applied Science 8% (+19%)
- Tissue Diagnostics 4% (+23%)<sup>1</sup>

All growth rates are in local currencies;  
<sup>1</sup>Sales from beginning Feb. '08, pro-forma stand-alone growth

## Roche IR Contacts:

Dr. Karl Mahler  
+41 (0)61 687 85 03  
karl.mahler@roche.com

Carla Bedard  
+41 (0)61 687 13 00  
carla\_christine.bedard@roche.com

Dr. Sabine Borngraeber  
+41 (0)61 688 80 27  
sabine.borngraeber@roche.com

Dr. Nicolas Dunant  
+41 (0)61 687 05 17  
nicolas.dunant@roche.com

Dianne Young  
+41 (0)61 688 93 56  
dianne.young@roche.com

## North American investors please contact:

Thomas Kudsk Larsen  
+1 973 235 36 55  
Mobile: +1 973 393 53 15  
thomas\_kudsk.larsen@roche.com

Nina Sachdev  
+1 973 562 2793  
nina.sachdev@roche.com

## General inquiries:

International: +41 (0)61 688 88 80  
North America: +1 973 562 22 33  
investor.relations@roche.com

F. Hoffmann-La Roche Ltd.  
Investor Relations  
CH-4070 Basel  
Switzerland

[www.roche.com/investors](http://www.roche.com/investors)

This fact sheet contains certain forward-looking statements. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in the sheet. For marketed products, please see full prescribing information on our website – [www.roche.com](http://www.roche.com). All mentioned trademarks are legally protected.

## Corporate Overview for Investors



## Our Business

Roche discovers, develops and delivers innovative diagnostic and therapeutic products and services that transform patients' lives and bring real benefits – from early detection and prevention of diseases to diagnosis, treatment and treatment-monitoring. Roche is pioneering the role that personalised medicine plays in the development of drugs and diagnostic tests.

Roche's Pharmaceuticals and Diagnostics divisions and our majority shareholdings in Genentech (USA) and Chugai (Japan) are the backbone of our innovation network. Worldwide, the Group employs approximately 90,000 people.

Roche's two divisions, Pharmaceuticals (CHF 35.9 billion sales in 2008) and Diagnostics (CHF 9.7 billion sales in 2008), are both market leaders.

Roche is the world leader in biotechnology. Five of Roche's 10 top selling medicines are manufactured using biotechnology, and biopharmaceuticals account for over 50% of our drug sales.

Roche has one of the strongest drug development pipelines in the industry: 41 phase III projects, 10 currently in registration. These include 62 new molecular entities and 57 additional indications for existing compounds.

Roche is recognised as a leader in Corporate Governance and Sustainability and is listed on the Dow Jones Sustainability Indices (DJSI) and the FTSE4Good Indices.

## Our Strategy


Only innovation can maintain the requisite quality of healthcare over the long term, our focus is on products and services offering medicinal value, not "me-too" treatments. Innovation is the core of our strategy and the key to safer, more cost-effective and more efficacious medicines.

As one of the world's leading healthcare companies, and given the combined strengths in pharmaceuticals and diagnostics, Roche is ideally positioned to lead in the development of personalised medicine.


The Roche Group's capabilities are augmented by technology collaborations and a constellation of world-wide alliances to develop individual products and entire product portfolios.

## Our Performance

Sales revenue from the Group's continuing businesses rose to CHF 45.6 billion in 2008. The group again achieved above market sales growth (+10% in local currencies excluding Tamiflu pandemic sales).




### Pharmaceutical and Diagnostic product sales above CHF 1 billion




## Our Growth

In 2008 operating profit (before exceptional items) was 4% up in local currencies vs. 2007 at approximately CHF 14 billion.



For 2008 a dividend of CHF 5.0 per share and non-voting equity security has been proposed for approval at the AGM on March 10<sup>th</sup> 2009. This would be the Group's twenty-second consecutive dividend increase.



The Roche Group's operating free cash flow has almost doubled over three years.

